Levetiracetam
- PDF / 169,361 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 33 Downloads / 155 Views
1 S
Elevation in serum creatine phosphokinase: 3 case reports In a retrospective study (involving 160 patients aged 9–188 months) conducted between January 2015 and January 2017 in Turkey, three patients [ages and sexes not stated] were described, who developed elevation in serum creatine phosphokinase (CPK) during treatment with levetiracetam for epilepsy [routes and durations of treatments to reactions onsets not stated]. The patients, who had epilepsy, started receiving levetiracetam at a starting dose of 10 mg/kg/day in the hospital. Subsequently, the patients developed elevation in their serum CPK levels. One of the 3 patients had serum CPK level of 943, and the other two patients had serum CPK levels of 1504, and 5046, respectively [units not stated]. Considering levetiracetam as the causative factor, the therapy was discontinued in all 3 patients. The patients were treated with hydration therapy to avoid potential complications. Consequently, the serum CPK levels gradually improved, and then normalised. Incecik F, et al. Effect of levetiracetam usage on serum creatine phosphokinase concentration in patients with epilepsy. Journal of Pediatric Neurosciences 15: 81-85, No. 2, 803520032 Apr-Jun 2020. Available from: URL: http://doi.org/10.4103/jpn.JPN_133_18
0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Dec 2020 No. 1834
Data Loading...
